Biogen hauls in $6B amid biopharma's M&A fever pitch

Days after Gilead Sciences ($GILD) spurred a wave of buyout rumors with its effort to bring in $10 billion, Biogen ($BIIB) laid out plans to raise $6 billion of its own, providing few details as it looks to bolster its cash position. The Cambridge, MA, drugmaker priced four series of senior notes, maturing between 2020 and 2045, in an offering expected to close next week. Some of the money will go toward a previously announced share repurchase program, the company said, with the rest tabbed for the vague "working capital and other general corporate purposes." More

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.